Actively Recruiting
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Led by M.D. Anderson Cancer Center · Updated on 2026-05-06
80
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
CONDITIONS
Official Title
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hematological malignancies showing CD70 expression ≥ 10% in tumor samples
- Meet disease-specific eligibility criteria
- At least 1 week since last cytotoxic chemotherapy before starting lymphodepleting chemotherapy (except Hydroxyurea as allowed)
- Localized radiotherapy allowed if other disease sites remain for response assessment
- Karnofsky performance score > 50% if >16 years old or Lansky score ≥ 50% if ≤16 years old
- Adequate organ function: renal, hepatic, cardiac, and pulmonary as specified
- Able to provide written informed consent
- Age between 12 and 80 years
- Weight of at least 40 kg
- Effective birth control for participants able to have children during study and 3 months after
- Signed consent for long-term follow-up
- Willing and able to provide informed consent or through a legally authorized representative
You will not qualify if you...
- Positive pregnancy test in females of childbearing potential or lactating females
- Grade 3 or higher toxicity from previous treatment
- Uncontrolled infections not responding to therapy
- HIV with detectable viral load
- Active neurological disorders
- Autoimmune disease within past 12 months
- Amyloidosis or POEMS syndrome
- Active brain or meningeal involvement by cancer
- Active acute or chronic graft-versus-host disease requiring therapy
- Other active malignancies except certain treated skin or cervical conditions
- Serious medical conditions deemed unsafe by investigator
- Major surgery within 4 weeks before chemotherapy
- Allogeneic stem cell transplant or donor lymphocyte infusion within 12 weeks before chemotherapy
- Use of other investigational or anti-cancer agents
- Systemic steroid therapy at time of NK cell infusion (except physiological doses)
- Recent use of antithymocyte globulin, lymphocyte immune globulin, or alemtuzumab
- Use of immunosuppressive therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
David Marin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here